Gilead Science (GILD) Followers Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gilead Science (GILD) Followers

GILD 124.62

-0.1%

11:08 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (255)	4/9/1997 2:58:00 AM
From: Doug Meetmer	of 961

The problem with treating Hep B is that the infection relapses after discontinuation of the suppressive drugs. In addition, it is one thing to show that LFTs improve on treatment, but a very different thing to show that on treatment a drug leads to fewer incidences of cirrhosis or hepatocellular carcinoma. Those studies would take years to complete. Naturally, there is a supposition that degree of chronic active hep B disease activity correlates with chance of developing cirrhosis. I think it would be wonderful for a person with chronic active Hep b to take a suppressive drug and dramatically lower his lifetime chances for development of cirrhosis or HCC. On the other hand, we wouldn't want to give someone a drug to take longterm if the only outcome is improvement in liver function tests but no change in incidence of cirrhosis or HCC. -DM

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next